News

Sep 30, 2025

Mabwell Published First-in-Human Study Results of Novel Anti-ST2 Monoclonal Antibody 9MW1911 at ERS 2025

➞

Sep 24, 2025

Mabwell Announces First Patient Dosed in the US Phase II Study of 9MW3011

➞

Sep 22, 2025

Mabwell Bioscience, Insilico Medicine, and ChemExpress Forging Ahead with ADC Innovation Through Strategic Collaboration

➞

Sep 20, 2025

New Drug Application of Mabwell's 9MW0813 for Injection Accepted by NMPA

➞

Sep 17, 2025

Mabwell Bioscience and Aditum Bio Announce Formation of Kalexo Bio to Advance Innovative siRNA Therapy for Cardiovascular Disorders

➞

Sep 05, 2025

Mabwell Secures Pakistan's First Denosumab Injection Approval

➞

Sep 02, 2025

First-in-Human Study Results of Mabwell's Novel Anti-ST2 Monoclonal Antibody 9MW1911 Selected for ERS 2025 Presentation

➞

Sep 01, 2025

Mabwell Announces NMPA Acceptance of IND Application for Novel Anti-IL-11 mAb 9MW3811 in Pathological Scarring

➞

Aug 19, 2025

Mabwell's CDH17-targeting ADC 7MW4911 Receives IND Clearance from FDA

➞

Aug 12, 2025

Mabwell Announces First Patient Dosed in the US Clinical Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated with ADCs

➞